Printer Friendly

Breast cancer and sense of smell.

About half of all breast cancers are estrogen-receptor positive, meaning the tumor cells require estrogen to grow. Women with estrogen-positive (ER+) breast cancers have a slight but statistically significant loss of their sense of smell, according to a report in the Aug. 10 LANCET from the Mt. Sinai School of Medicine in New York City.

Steven Lehrer and his colleagues looked at 25 women with ER+ breast cancers, 21 women with estrogen-receptor negative (ER-) cancers and 46 cancer-free women matched with these two groups for age, sex, race and smoking habits. Four ER+ women and five ER- women had received chemotherapy; none had received radiation treatments to the head.

The ER+ women scored significantly lower than the ER- and control groups on a sophisticated and sensitive scratch-and-sniff test. The difference didn't represent functional impairmant, and, says Lehrer, "the women didn't seem to notice."

The biological connection between ER+ breast cancer and sense of smell may lie in the pineal gland, a small organ in the brain that secrets the hormone melatonin in response to day length. In rats, removing the pineal gland or inhibiting melatonin can induce mammary tumors; the nightly melatonin peak in women with ER+ breast cancer is lower than in other women.

"Perhaps," the researchers suggest, "both the pineal and olfactory abnormalities observed in women with ER+ breast cancer result from a single underlying defect." What it means in terms of treatment "is difficult to say," notes Lehrer. Perhaps, he speculates, a sense-of-smell test may prove a good screen.
COPYRIGHT 1985 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1985, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:statistically significant loss of smell in breast cancer patients
Publication:Science News
Date:Sep 7, 1985
Words:252
Previous Article:Sure, I can stop at one Milk Dud ... really.
Next Article:Microbial foot soldiers.
Topics:


Related Articles
Fat chance: predicting breast cancer's course.
Beating breast cancer: researchers are looking beyond conventional surgeries and chemotherapy.
Drugs give slight edge in breast cancer.
Diet and cancer: timing makes a difference.
Best time to beat breast cancer?
Predicting the return of breast cancer.
Cancer patients accentuate the positive.
Limited Expression of C-erbB-2 in Node Negative Breast Cancer Patients.
Metastatic breast cancer manifested as refractory anemia and gastric polyps.
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters